AELIX-002

View all the clinical researches

Collaboration on clinical research

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines DNA.HTI and MVA.HTI in Early Treated HIV-1 Positive Individuals

07/07/2017 - 31/12/2021

Type of research: Intervenció Promoter: Aelix Therapeutics Principal Investigators: Beatriz Mothe Participating entities: Hospital Germans Trias i Pujol, IrsiCaixa, AELIX Therapeutics
  • Design: Aleatoritzat, doble cec, controlat amb placebo
  • Phase: I
  • Sample size: 45
  • NCT03204617

Subscribe to our newsletter

Back to Top
Irsi Caixa

Promoted by:

'La Caixa' Foundation Generalitat de Catalunya - Departament de Salut

 

HR Excellence in Research

Member of:

Cerca

In cooperation with: